Sign In to Follow Application
View All Documents & Correspondence
View All Documents & Correspondence
Gip/Glp1/Gcg Tri Receptor Agonists And Uses Thereof
Abstract: Polypeptides are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The polypeptides have structural features resulting in activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases and/or conditions such as obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, Chronic Kidney Disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).
Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence
Notices, Deadlines & Correspondence
Patent Information
Application #
Filing Date
05 August 2025
Publication Number
37/2025
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
Parent Application
Applicants
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, Indiana 46285
Inventors
1. ABRAHAM, Milata Mary
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
2. BROWN, Robert Andrew
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
3. COSKUN, Tamer
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
4. FLORA, David Benjamin
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
5. KLEINDL, Paul Joseph
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
6. QU, Fucheng
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
7. QU, Hongchang
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
8. WALLIS, James Lincoln
c/o ELI LILLY AND COMPANY
P.O. Box 6288
Indianapolis, Indiana 46206-6288
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202517074521-STATEMENT OF UNDERTAKING (FORM 3) [05-08-2025(online)].pdf | 2025-08-05 |
| 2 | 202517074521-Sequence Listing in XML (WIPO ST26) [05-08-2025(online)].pdf | 2025-08-05 |
| 3 | 202517074521-Sequence Listing in PDF [05-08-2025(online)].pdf | 2025-08-05 |
| 4 | 202517074521-REQUEST FOR EXAMINATION (FORM-18) [05-08-2025(online)].pdf | 2025-08-05 |
| 5 | 202517074521-FORM 18 [05-08-2025(online)].pdf | 2025-08-05 |
| 6 | 202517074521-FORM 1 [05-08-2025(online)].pdf | 2025-08-05 |
| 7 | 202517074521-DECLARATION OF INVENTORSHIP (FORM 5) [05-08-2025(online)].pdf | 2025-08-05 |
| 8 | 202517074521-COMPLETE SPECIFICATION [05-08-2025(online)].pdf | 2025-08-05 |
| 9 | 202517074521-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [05-08-2025(online)].pdf | 2025-08-05 |
| 11 | 202517074521-RELEVANT DOCUMENTS [19-08-2025(online)].pdf | 2025-08-19 |
| 12 | 202517074521-MARKED COPIES OF AMENDEMENTS [19-08-2025(online)].pdf | 2025-08-19 |
| 13 | 202517074521-FORM 13 [19-08-2025(online)].pdf | 2025-08-19 |
| 14 | 202517074521-AMMENDED DOCUMENTS [19-08-2025(online)].pdf | 2025-08-19 |
| 15 | 202517074521-FORM-26 [08-09-2025(online)].pdf | 2025-09-08 |
| 16 | 202517074521-Proof of Right [22-10-2025(online)].pdf | 2025-10-22 |
| 17 | 202517074521-FORM 3 [22-10-2025(online)].pdf | 2025-10-22 |
| 18 | 202517074521-RELEVANT DOCUMENTS [12-11-2025(online)].pdf | 2025-11-12 |
| 19 | 202517074521-MARKED COPIES OF AMENDEMENTS [12-11-2025(online)].pdf | 2025-11-12 |
| 20 | 202517074521-FORM 13 [12-11-2025(online)].pdf | 2025-11-12 |
| 21 | 202517074521-Annexure [12-11-2025(online)].pdf | 2025-11-12 |
| 22 | 202517074521-AMMENDED DOCUMENTS [12-11-2025(online)].pdf | 2025-11-12 |